Illumina (NASDAQ:ILMN) Insider Scott Davies Sells 615 Shares

Illumina, Inc. (NASDAQ:ILMN) insider Scott Davies sold 615 shares of Illumina stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the sale, the insider directly owned 20,338 shares of the company’s stock, valued at $4,067,600. This represents a 2.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Illumina Stock Performance

ILMN stock opened at $198.16 on Tuesday. The business’s fifty day moving average is $177.78 and its 200-day moving average is $147.61. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The company has a market cap of $29.98 billion, a P/E ratio of 36.97, a price-to-earnings-growth ratio of 2.94 and a beta of 1.44. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $207.00.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Equities research analysts forecast that Illumina, Inc. will post 5.37 EPS for the current year.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Raised revenue outlook and clinical-sequencing demand support the stock. Illumina reported second-quarter revenue of $1.159 billion, up from $1.059 billion a year earlier, and raised its 2026 revenue forecast to $4.60 billion-$4.64 billion. Management’s focus on clinical sequencing and multi-omics is reinforcing expectations for continued growth. Why Illumina Is Up After Raising 2026 Revenue Outlook
• Positive Sentiment: Analysts raised their valuation expectations. Piper Sandler reaffirmed its “overweight” rating and increased its price target to $225 from $200. Other recent reports cited price targets of $210 and $230, indicating that some analysts see additional upside despite the stock’s recent rally. Piper Sandler Rating Report Illumina Price Target Raised to $210 Illumina Price Target Raised to $230
• Neutral Sentiment: Momentum is strong, but investors are questioning how much upside remains. ILMN reached a fresh 52-week high after more than doubling over the past year. The move reflects improving fundamentals, but the elevated share price increases sensitivity to any execution or guidance disappointment. Illumina Hits Fresh High
• Negative Sentiment: Valuation and cash-flow concerns could weigh on returns. One analysis estimates the shares may be approximately 19% overvalued, while another notes that market multiples appear expensive even though a discounted-cash-flow model suggests potential upside. Broader concerns include whether strong cash generation will translate into efficient spending and sustained growth. Illumina Could Be Overvalued Cash-Producing Stocks That Concern Us
• Negative Sentiment: An insider sold shares. Scott M. Davies sold 615 shares worth $123,000 under a pre-arranged Rule 10b5-1 plan. The sale was relatively small and leaves him with 20,338 shares, but it is still a modest negative signal for sentiment.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC raised its position in Illumina by 113.7% in the 1st quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after buying an additional 4,940 shares during the last quarter. Sivia Capital Partners LLC acquired a new position in Illumina during the 2nd quarter worth approximately $621,000. CW Advisors LLC bought a new position in shares of Illumina during the 2nd quarter worth approximately $275,000. Marshall Wace LLP grew its stake in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC raised its holdings in shares of Illumina by 30.9% in the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on ILMN shares. Royal Bank Of Canada increased their price target on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research report on Friday. TD Cowen lifted their price target on shares of Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday. Guggenheim upped their price objective on shares of Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research report on Friday. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Stifel Nicolaus raised their price target on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday. Eight analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.